CXCL12 and plasma cell myeloma: In vivo, olaptesed-pegol neutralize CXCL12, leading to a bone marrow microenvironment that is less receptive for multiple myeloma cells and reduces multiple myeloma cell homing and growth (Roccaro et al., 2014).